早期给予利托那韦增强型洛匹那韦可预防重症新型冠状病毒肺炎。 - Suppr

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.

作者信息

Klement-Frutos Elise, Burrel Sonia, Peytavin Gilles, Marot Stéphane, Lê Minh P, Godefroy Nagisa, Calvez Vincent, Marcelin Anne-Geneviève, Caumes Eric, Pourcher Valérie, Boutolleau David

机构信息

Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France.

出版信息

J Infect. 2021 Jan;82(1):159-198. doi: 10.1016/j.jinf.2020.05.039. Epub 2020 May 27.

DOI:10.1016/j.jinf.2020.05.039

PMID:32473230

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7251410/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30c3/7251410/97f3b7128daa/gr1_lrg.jpg

相似文献

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.早期给予利托那韦增强型洛匹那韦可预防重症新型冠状病毒肺炎。

J Infect. 2021 Jan;82(1):159-198. doi: 10.1016/j.jinf.2020.05.039. Epub 2020 May 27.

Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.洛匹那韦/利托那韦治疗严重急性呼吸综合征、中东呼吸综合征和 COVID-19：系统评价。

Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592-8605. doi: 10.26355/eurrev_202008_22659.

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.洛匹那韦/利托那韦未能缩短台湾轻症肺炎患者 SARS-CoV-2 脱落持续时间。

J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.

Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study.洛匹那韦/利托那韦与 COVID-19 合并流感感染患者肺炎的消退相关：一项回顾性配对病例对照研究。

J Med Virol. 2021 Jan;93(1):472-480. doi: 10.1002/jmv.26260. Epub 2020 Jul 15.

Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.洛匹那韦/利托那韦联合治疗非重症 COVID-19 患者中病毒动力学及快速病毒清除相关因素。

Eur Rev Med Pharmacol Sci. 2020 May;24(10):5788-5796. doi: 10.26355/eurrev_202005_21373.

Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.

Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.洛匹那韦/利托那韦作为 SARS-CoV-2 感染抗病毒方案中的第三种药物。

J Chemother. 2021 May;33(3):193-197. doi: 10.1080/1120009X.2020.1775424. Epub 2020 Jun 12.

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.新加坡 2019 年新型冠状病毒肺炎患者的流行病学特征和临床病程

JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.

In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.在重症 COVID-19 患者中，加用洛匹那韦-利托那韦联合常规治疗未能改善 28 天死亡率。

Ann Intern Med. 2021 Jan;174(1):JC3. doi: 10.7326/ACPJ202101190-003. Epub 2021 Jan 5.

[Chloroquine as a possible treatment for COVID-19].[氯喹作为新型冠状病毒肺炎的一种可能治疗方法]

Ned Tijdschr Geneeskd. 2020 Mar 11;164:D4936.

引用本文的文献

Lopinavir enhances anoikis by remodeling autophagy in a circRNA-dependent manner.洛匹那韦通过环状 RNA 依赖的方式重塑自噬来增强失巢凋亡。

Autophagy. 2024 Jul;20(7):1651-1672. doi: 10.1080/15548627.2024.2325304. Epub 2024 Mar 8.

Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics.通过分子对接和生物信息学从苗药中筛选治疗糖尿病和新冠肺炎的化合物。

Arab J Chem. 2023 Sep;16(9):105001. doi: 10.1016/j.arabjc.2023.105001. Epub 2023 May 18.

Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19.新冠病毒感染后综合征。SARS-CoV-2 病毒 RNA 在新冠病毒感染后持续有症状患者的血浆、粪便和尿液中的检测。

BMC Infect Dis. 2022 Mar 3;22(1):211. doi: 10.1186/s12879-022-07153-4.

Knowledge, Attitude, Behavior, and Socioeconomic Conditions of People Living with HIV in Indonesia During the COVID-19 Pandemic: A Cross-Sectional Study.COVID-19大流行期间印度尼西亚艾滋病毒感染者的知识、态度、行为和社会经济状况：一项横断面研究。

HIV AIDS (Auckl). 2021 Dec 14;13:1045-1054. doi: 10.2147/HIV.S333469. eCollection 2021.

Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies.对 SARS-CoV-2 病毒动力学进行系统回顾和患者水平荟萃分析，以建立对抗病毒疗法反应的模型。

Clin Pharmacol Ther. 2021 Aug;110(2):321-333. doi: 10.1002/cpt.2223. Epub 2021 May 1.

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.洛匹那韦/利托那韦：将一种旧药用于新型冠状病毒肺炎治疗中的艾滋病毒感染治疗。

Biomed J. 2021 Mar;44(1):43-53. doi: 10.1016/j.bj.2020.11.005. Epub 2020 Nov 10.

Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.早期洛匹那韦/利托那韦不能降低COVID-19患者的死亡率：一项大型多中心研究的结果。

J Infect. 2021 Jun;82(6):276-316. doi: 10.1016/j.jinf.2021.02.011. Epub 2021 Feb 11.

Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.洛匹那韦利托那韦早期治疗重症 COVID-19 患者的疗效：一项病例系列研究。

Clin Med (Lond). 2021 Jan;21(1):e80-e83. doi: 10.7861/clinmed.2020-0348. Epub 2020 Dec 18.

Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.洛匹那韦/利托那韦治疗新型冠状病毒肺炎的疗效与安全性：一项系统评价与Meta分析

Trop Med Infect Dis. 2020 Nov 28;5(4):180. doi: 10.3390/tropicalmed5040180.

Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review.抗逆转录病毒药物预防 COVID-19：全面文献综述。

J Clin Pharmacol. 2021 May;61(5):581-590. doi: 10.1002/jcph.1788. Epub 2020 Dec 6.

本文引用的文献

Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.与 SARS-CoV-2 感染住院非重症患者病毒持续排出相关因素及洛匹那韦/利托那韦治疗的影响。

Eur Respir J. 2020 Jul 16;56(1). doi: 10.1183/13993003.00799-2020. Print 2020 Jul.

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.从 FDA 批准药物中鉴定抗 SARS-CoV-2 的抗病毒候选药物。

Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00819-20.

The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris Area.巴黎地区一名医护人员首次出现本地获得性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。

Clin Infect Dis. 2020 Dec 3;71(9):e530-e531. doi: 10.1093/cid/ciaa171.

Drug targets for corona virus: A systematic review.冠状病毒的药物靶点：系统评价。

Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65. doi: 10.4103/ijp.IJP_115_20. Epub 2020 Mar 11.

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。

N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.利巴韦林联合洛匹那韦/利托那韦与洛匹那韦/利托那韦单独治疗 2019 年冠状病毒病：一项回顾性队列研究。

J Infect. 2020 Jul;81(1):e1-e5. doi: 10.1016/j.jinf.2020.03.002. Epub 2020 Mar 11.

Covid-19 - Navigating the Uncharted.新冠疫情——探索未知领域。

N Engl J Med. 2020 Mar 26;382(13):1268-1269. doi: 10.1056/NEJMe2002387. Epub 2020 Feb 28.

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.实时 RT-PCR 检测 2019 新型冠状病毒（2019-nCoV）

Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000045.

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.洛匹那韦/利托那韦治疗严重急性呼吸综合征：一项多中心回顾性匹配队列研究。

Hong Kong Med J. 2003 Dec;9(6):399-406.

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.冠状病毒相关严重急性呼吸综合征肺炎社区暴发中的临床进展与病毒载量：一项前瞻性研究。

Lancet. 2003 May 24;361(9371):1767-72. doi: 10.1016/s0140-6736(03)13412-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献